Phosphate binders: hold the calcium?

@article{Bushinsky2006PhosphateBH,
  title={Phosphate binders: hold the calcium?},
  author={David A. Bushinsky},
  journal={Clinical journal of the American Society of Nephrology : CJASN},
  year={2006},
  volume={1 4},
  pages={
          695-6
        }
}
  • D. Bushinsky
  • Published 1 July 2006
  • Medicine
  • Clinical journal of the American Society of Nephrology : CJASN
Several retrospective studies of large databases have shown that most dialysis patients have elevated levels of serum phosphorus and that this elevation, independent of a variety of relevant variables, adversely affects patient survival (1,2). Although there are no data demonstrating that a reduction of serum phosphorus will improve survival, a prudent clinician cannot dismiss this compelling epidemiologic evidence and will strive to lower serum phosphorus in dialysis patients. Although the… Expand
Oral phosphate binders.
TLDR
Dialysis patient outcomes are worse than outcomes for many types of cancer, yet prospective, outcome-based randomized controlled trials are not being undertaken for reasons that are difficult to explain. Expand
Contemporary management of phosphorus retention in chronic kidney disease: a review
  • F. Amiri
  • Medicine
  • Clinical and Experimental Nephrology
  • 2015
TLDR
FGF-23 appears as a promising target for novel therapeutic approaches to improve clinical outcomes of CKD patients and Bixalomer is a new Ca-free, metal- free, potent phosphate binder, non-hydrochloride, and non- absorbing polymer, which improves metabolic acidosis. Expand
Pharmacology, efficacy and safety of oral phosphate binders
TLDR
The role of phosphate control in determining patient outcomes must be quantified, which is likely to require a large randomized, controlled study of two levels of phosphate controlled by Oral phosphate binders. Expand
Calcium Balance with Automated Peritoneal Dialysis
TLDR
The present study demonstrates the importance of UF and iCa in determining transperitoneal Ca transport, given the widening use of calcimimetic agents, vitamin D analogs, and Ca-based phosphate binders and the potential association between UF rate and outcome in PD patients. Expand
Clinical application of calcium modeling in patients with chronic kidney disease.
  • D. Bushinsky
  • Medicine
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2012
TLDR
While bone can respond to stress by altering its mass and architecture, calcium balance is not being detected, and the clinical examples of primary hyperparathyroidism and adolescent bone growth teach us that blood calcium concentration and mass balance are not necessarily linked. Expand
Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
TLDR
There is insufficient data to establish the comparative superiority of non-calcium-binding agents over calcium-containing phosphate binders for such important patient-level outcomes as all-cause mortality and cardiovascular end points, and suboptimal reporting of study methods to determine trial quality. Expand
Phosphate binders for preventing and treating bone disease in chronic kidney disease patients.
TLDR
There is insufficient data to establish the comparative superiority of novel non-calcium binding agents over calcium-containing phosphate binders for patient-level outcomes such as all-cause mortality and cardiovascular end-points in CKD. Expand
Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study.
TLDR
Magnesium carbonate was generally well-tolerated in this selected patient population, and was effective in controlling serum phosphorus while reducing elemental calcium ingestion. Expand
Phosphorus Metabolism
Phosphorus plays a pivotal role in various biological processes. Therefore, a deeper understanding of Phosphorus Homeostasis is essential for management and treatment of conditions causing anExpand
VASCULAR CALCIFICATION IN PATIENTS WITH KIDNEY DISEASE: Vascular Calcification—A New Window on the Cardiovascular System: Role of Agents Used to Manipulate Skeletal Integrity
TLDR
The most relevant data from several trials is reviewed, examining the impact of several drugs used to correct abnormalities of mineral metabolism in renal patients and the KDIGO classification, aimed to create a common language among nephrologists. Expand
...
1
2
...

References

SHOWING 1-10 OF 19 REFERENCES
The case against calcium-based phosphate binders.
  • S. Moe, G. Chertow
  • Medicine
  • Clinical journal of the American Society of Nephrology : CJASN
  • 2006
TLDR
Calcium-based phosphate binders should be avoided in many, if not most, patients who are undergoing dialysis, because of the compelling biologic plausibility that hyperphosphatemia and excess exogenous calcium administration can accelerate vascular calcification. Expand
Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study.
TLDR
This study expands the understanding of the relationship between altered mineral metabolism and outcomes and identifies several potential opportunities for improved practice in this area. Expand
Calcium-based phosphate binders are appropriate in chronic renal failure.
  • E. Friedman
  • Medicine
  • Clinical journal of the American Society of Nephrology : CJASN
  • 2006
TLDR
The case for and against abandoning calcium-based phosphate binders in favor of sevelamer is reviewed, and an open mind and an awareness of developing literature are necessary when deciding how to manage hyperphosphatemia in renal failure. Expand
Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.
TLDR
Hyperphosphatemia and hyperparathyroidism were significantly associated with all-cause, cardiovascular, and fracture-related hospitalization, and the population attributable risk percentage for disorders of mineral metabolism was 17.5%, owing largely to the high prevalence of hyperph phosphatemia. Expand
Study of intestinal absorption of calcium in patients with renal failure.
TLDR
True intestinal calcium absorption is clearly impaired with renal failure although the defect cannot be detected with mild renal failure, and the impairment is discussed in relation to the kidney's role in producing 1,25-dihydroxycholecalciferol, the presumed active form of vitamin D. Expand
Progressive accumulation of lanthanum in the liver of normal and uremic rats.
TLDR
La accumulates in tissues, most strikingly in the liver, and renal failure accelerates the accumulation, while this was a relatively short-term study, La accumulation increased in a time-dependent manner. Expand
Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients.
TLDR
Compared with calcium-based phosphate binders, sevelamer is less likely to cause hypercalcemia, low levels of PTH, and progressive coronary and aortic calcification in hemodialysis patients. Expand
Serum phosphate levels and mortality risk among people with chronic kidney disease.
TLDR
Elevated serum phosphate levels were independently associated with increased mortality risk among this population of patients with chronic kidney disease and were associated with a significantly increased risk for death. Expand
Factors for increased morbidity and mortality in uremia: hyperphosphatemia.
TLDR
Evaluating the significance of hyperphosphatemia in hemodialysis patients, current therapeutic approaches, and a new model for evaluating the dialysis prescription for iP balance are described. Expand
Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis.
TLDR
New hemodialysis patients with no evidence of coronary calcification showed little evidence of disease development over 18 months independent of phosphate binder therapy, however, subjects with evidence of at least mild coronary calcify had significant progression at 6, 12, and 18 months. Expand
...
1
2
...